Home  »  Companies   »  If You Don’t Buy Deciphera Pharmaceuticals I...

If You Don’t Buy Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Now, You’ll Regret It Later

The trading price of Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) closed higher on Tuesday, June 21, closing at $12.42, 5.79% higher than its previous close.

Traders who pay close attention to intraday price movement should know that it fluctuated between $11.82 and $12.69. In examining the 52-week price action we see that the stock hit a 52-week high of $38.91 and a 52-week low of $6.51. Over the past month, the stock has gained 9.23% in value.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Deciphera Pharmaceuticals Inc., whose market valuation is $764.95 million at the time of this writing, is expected to release its quarterly earnings report May 02, 2022 – May 06, 2022. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.66 per share this quarter, however they have predicted annual earnings per share of -$2.66 for 2022 and -$2.19 for 2023. It means analysts are expecting annual earnings per share growth of 48.40% this year and 17.70% next year.

Analysts have forecast the company to bring in revenue of $30.69 million for the current quarter, with the likely lows of $28.44 million and highs of $33.5 million. The average estimate suggests sales will likely up by 30.20% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2022 is $126.36 million. The company’s revenue is forecast to grow by 31.40% over what it did in 2022.

A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Deciphera Pharmaceuticals Inc. 4 upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest DCPH has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.

Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned DCPH a recommendation rating is 11. Out of them, 6 rate it a Hold, while 3 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Deciphera Pharmaceuticals Inc. (DCPH) as Underweight, while 2 advise Sell. Analysts have rated the stock Hold, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.

A quick review shows that DCPH’s price is currently 10.24% off the SMA20 and 15.60% off the SMA50. The RSI metric on the 14-day chart is currently showing 59.06, and weekly volatility stands at 8.07%. When measured over the past 30 days, the indicator reaches 7.24%. Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH)’s beta value is currently sitting at 1.27, while the Average True Range indicator is currently displaying 0.86. With analysts defining $6.00-$15.00 as the low and high price targets, we arrive at a consensus price target of $10.78 for the trailing 12-month period. The current price is about 51.69% off the estimated low and -20.77% off the forecast high, based on this estimate. Investors will be thrilled if DCPH’s share price rises to $11.00, which is the median consensus price. At that level, DCPH’s share price would be 11.43% above current price.

To see how Deciphera Pharmaceuticals Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: DCPH stock’s performance was 5.79% in the latest trading, and -66.59% in the past year, while Pieris Pharmaceuticals Inc. (PIRS) has traded 2.99% on the day and positioned -50.43% lower than it was a year ago. Also in last trading session, the S&P 500 Index has surged 2.45%, while the Dow Jones Industrial also saw a positive session, up 2.15% on the day.

An evaluation of the daily trading volume of Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) indicates that the 3-month average is 1.27 million.

Currently, records show that 58.62 million of the company’s shares remain outstanding. The insiders hold 27.70% of outstanding shares, whereas institutions hold 68.00%. However, since the stock’s price has seen 27.12% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]